Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 17, 2023

Efficacy of Enasidenib and Risk-Adapted Addition of Azacitidine in Patients With Newly Diagnosed IDH2-Mutant AML

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
Blood Adv 2023 Oct 23;[EPub Ahead of Print], SF Cai, Y Huang, JR Lance, HCC Mao, A Dunbar, S McNulty, TE Druley, Y Li, MR Baer, W Stock, T Kovacsovics, W Blum, GJ Schiller, RL Olin, JM Foran, MR Litzow, TL Lin, PA Patel, MC Foster, M Boyiadzis, RH Collins, J Chervin, AB Shoben, JA Vergilio, NA Heerema, L Rosenberg, TL Chen, AO Yocum, F Druggan, S Marcus, M Stefanos, BJ Druker, AS Mims, U Borate, A Burd, JC Byrd, RL Levine, EM Stein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading